Clinical trial
Transdermal (TDS) Oxybutynin (Oxytrol(r)) in Overactive Bladder
NCT00224146 · Watson Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00224146 |
|---|---|
| Title | Transdermal (TDS) Oxybutynin (Oxytrol(r)) in Overactive Bladder |
| Official title | Multicenter Assessment of Transdermal Therapy in Overactive Bladder With Oxybutynin TDS (MATRIX) |
| Acronym | MATRIX |
| Lead sponsor | Watson Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Overactive Bladder, Urinary Incontinence, Quality of Life |
| Intervention type | Drug |
| Interventions | oxybutynin transdermal delivery system (Oxytrol(r)) |
| Enrollment | 2,878 |
| Start date | May 1, 2004 |
| Primary completion | May 1, 2005 |
| Completion | May 1, 2005 |
| First posted | Sep 22, 2005 |
| Last update posted | Nov 30, 2011 |
| Countries | United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: